Could cause temporary or reversible harm; serious harm is unlikely.
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
| Brand name | PRAZOSIN HYDROCHLORIDE |
| Generic name | PRAZOSIN HYDROCHLORIDE |
| Active ingredient(s) | PRAZOSIN HYDROCHLORIDE |
| Distributed by / for | American Health Packaging, Columbus, Ohio 43217, Carton |
| NDC | 68084-996-01 |
| Full product label | Prazosin Hydrochloride, Capsules, USP, 1 mg, 100 capsules (10x10) cartons, Rx only, Distributed by American Health Packaging, Columbus, Ohio 43217, Carton NDC 68084-996-01. Individual unit dose: NDC 68084-996-11 |
| Recalling firm | Amerisource Health Services LLC |
| Distribution | Nationwide within the United States |
| Quantity | 1,970 cartons |
| Recall initiated | 2025-10-16 |
| Report date | 2025-11-05 |
| Recall completed | — |
| Recall number | D-0101-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Columbus OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗